Vaccine introduction grants and operational support for campaigns

Aurélia Nguyen

GAVI Alliance Board meeting
Washington, DC, USA, 12-13 June 2012
Background: Vaccine introduction grants

- Until March 2012, GAVI had disbursed ~ 150 vaccine introduction grants (US$ 28.6m total).

- Revised policy: US$ 100,000 or US$ 0.30/child in birth cohort

- Policy under review to better serve newer vaccines

Newer vaccines: pneumococcal, rotavirus, HPV, rubella campaigns
Objective, scope and operating guidelines

- **Objective**
  - Facilitate timely, effective implementation of critical activities:
    - Before new vaccine introductions
    - For delivery during campaigns
  - One-time investments, covering a share of the cost

- **Scope**
  - All new GAVI-supported vaccines
  - Activities driven by country needs
  - Does not cover recurrent costs

- **Operating guidelines**
  - Flexible, timely, simple, separate from other cash support, not used for co-financing
Recommended policy: what has changed?

**GAVI support:**
- Current policy

**Total cost estimate:**
- Current policy

---

- **Infant vaccines (per child):** $0.0
- **HPV vaccines (per girl):** $0.6
- **Operational support campaigns (per target):** $1.2
Recommended policy: what has changed?

- Infant vaccines (per child): $0.0 - $2.4
- HPV vaccines (per girl): $0.0 - $2.4
- Operational support campaigns (per target): $0.0 - $2.4

GAVI support:
- Current policy
- New policy

Total cost estimate:
- Current policy
- New policy

GAVI Alliance Board meeting
12-13 June 2012
Recommended policy: funding levels

1. Vaccine introduction grants:
   - Vaccines delivered to infants: US$ 0.80 per child in birth cohort (min. US$ 100,000)
   - HPV vaccines delivered to adolescent girls: US$ 2.40 per girl in target population (min. US$ 100,000)

2. Operational support for campaigns:
   - US$ 0.65 per individual in target population

3. Product switches after first introduction:
   - One third of full grant for transition to new product, provided criteria are met
Implementation

- Effective date: September 2012
- TAP applies, mandatory audits for grants >US$ 250k
- Policy updates:
  - Every 2 years: funding levels, financial management requirements
  - 2017: full policy review
- Enabling factors:
  - Enhanced financial and technical support from GAVI Alliance partners
  - Improved knowledge base on actual costs and financing
Projected financial implications for GAVI*

- Total projected **incremental** cost to GAVI for 2012-2015 **US$ 262m**, of which:
  - US$ 65m for vaccine introduction grants (154 grants)
  - US$192m for operational support for campaigns (55 campaigns)
  - US$6m for product switches

* Based on SDFv.5, excluding India; red bars include routine introductions of MR vaccines after GAVI supported campaigns
Projected financial implications for GAVI

- US$ 61m additional cost for already approved proposals introducing after Sept 2012
- 5.4% of projected GAVI expenditures (2.4% under current policy) 2012–2020
- Cash support closely linked to immunisation outcomes
- Fits within 15%–25% target for cash support
Recommendations to the GAVI Board

- The Programme and Policy Committee (PPC) recommends that the GAVI Alliance Board:
  - **Approves** the GAVI vaccine introduction grant and operational support for campaigns policy (the “Policy”), as described in Annex 1 of Doc 13;
  - **Requests** the Secretariat to make the necessary arrangements to ensure that vaccine introductions and campaigns occurring on or after 1 September 2012 benefit from the Policy regardless of when the country proposal was approved.